{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-071528","form_type":"8-K","ticker":"SLNO","cik":"0001484565","company_name":"SOLENO THERAPEUTICS INC","filed_at":"2026-02-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.177456+00:00","generated_at":"2026-05-16T00:14:42.053437+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Soleno posts Q4 2025 product revenue of $91.7M; full-year net income $20.9M from VYKAT XR launch","bullets":["FY 2025 net income $20.9M ($0.40 basic EPS) vs. net loss of $175.9M in 2024.","Q4 2025 product revenue $91.7M; full-year revenue $190.4M from VYKAT XR (diazoxide choline).","859 active patients on drug as of Dec 31, 2025; 1,250 patient start forms received since approval.","Cash, cash equivalents and marketable securities $506.1M at year end; $100M share repurchase executed.","First commercial milestone ($7.0M) achieved in Q4 2025; payment due Q1 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-071528","json":"https://secwatch.observer/filing/0001193125-26-071528.json","markdown":"https://secwatch.observer/filing/0001193125-26-071528.md","text":"https://secwatch.observer/filing/0001193125-26-071528.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1484565/000119312526071528/0001193125-26-071528-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1484565/000119312526071528/d251192d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T00:14:42.053437+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}